Dr. Antonio Fojo, MD, PhD
Claim this profileJames J. Peters VA Medical Center, Bronx, NY
Studies Prostate Cancer
Studies RAD51 Gene Mutation
3 reported clinical trials
5 drugs studied
Area of expertise
1Prostate Cancer
Stage IV
MLH1 positive
MSH2 positive
2RAD51 Gene Mutation
Stage IV
RAD51 positive
RAD51C positive
Affiliated Hospitals
Clinical Trials Antonio Fojo, MD, PhD is currently running
Pembrolizumab
for Prostate Cancer
The primary objective is to assess the activity and efficacy of pembrolizumab, a checkpoint inhibitor, in Veterans with metastatic castration-resistant prostate cancer (mCRPC) characterized by either mismatch repair deficiency (dMMR) or biallelic inactivation of CDK12 (CDK12-/-). The secondary objectives involve determining the frequency with which dMMR and CDK12-/- occur in this patient population, as well as the effects of pembrolizumab on various clinical endpoints (time to PSA progression, maximal PSA response, time to initiation of alternative anti-neoplastic therapy, time to radiographic progression, overall survival, and safety and tolerability). Lastly, the study will compare the pre-treatment and at-progression metastatic tumor biopsies to investigate the molecular correlates of resistance and sensitivity to pembrolizumab via RNA-sequencing, exome-sequencing, selected protein analyses, and multiplexed immunofluorescence.
Recruiting2 awards Phase 23 criteria
Radium-223 + Docetaxel
for Prostate Cancer
The purpose of this study is to compare any good and bad effects of using radium-223 along with docetaxel chemotherapy treatment versus using docetaxel alone. Earlier studies helped show that the combination is safe, but the combination has not been proven to work better than either drug alone. The goal of this study is to find out if combining docetaxel and radium-223 is better than giving either drug by itself.
Recruiting2 awards Phase 323 criteria
More about Antonio Fojo, MD, PhD
Clinical Trial Related4 years of experience running clinical trials · Led 3 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Antonio Fojo, MD, PhD has experience with
- Carboplatin
- Olaparib
- Radium-223
- Docetaxel
- Pembrolizumab
Breakdown of trials Antonio Fojo, MD, PhD has run
Prostate Cancer
RAD51 Gene Mutation
Breast and Ovarian Cancer Syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Antonio Fojo, MD, PhD specialize in?
Antonio Fojo, MD, PhD focuses on Prostate Cancer and RAD51 Gene Mutation. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are MLH1 positive.
Is Antonio Fojo, MD, PhD currently recruiting for clinical trials?
Yes, Antonio Fojo, MD, PhD is currently recruiting for 3 clinical trials in Bronx New York. If you're interested in participating, you should apply.
Are there any treatments that Antonio Fojo, MD, PhD has studied deeply?
Yes, Antonio Fojo, MD, PhD has studied treatments such as Carboplatin, Olaparib, Radium-223.
What is the best way to schedule an appointment with Antonio Fojo, MD, PhD?
Apply for one of the trials that Antonio Fojo, MD, PhD is conducting.
What is the office address of Antonio Fojo, MD, PhD?
The office of Antonio Fojo, MD, PhD is located at: James J. Peters VA Medical Center, Bronx, NY, Bronx, New York 10468 United States. This is the address for their practice at the James J. Peters VA Medical Center, Bronx, NY.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.